Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

NCT04821063 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne and Becker Muscular Dystrophy
Polycytemia Vera

Interventions

DRUG: ITF2357 10 mg/mL
DRUG: ITF2357 10 mg/mL
DRUG: Placebo
DRUG: Moxifloxacin Hydrochloride
DRUG: Placebo

Sponsor

Italfarmaco